MedTrace Logo

VEG111485: A QTc Study of Pazopanib

NCT00861029 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-11-14

No results posted yet for this study

Summary

This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will serve as a positive control.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Pazopanib

Subjects treated with pazopanib

OTHER

Placebo for pazopanib

Control for comparison with pazopanib

DRUG

Moxifloxacin

Comparator for pazopanib

OTHER

Placebo for moxifloxacin

Placebo for moxifloxacin

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-19
Primary Completion
2010-02-15
Completion
2010-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861029 on ClinicalTrials.gov